Because HER2/neu proto-oncogene overexpression significantly contributes to the malignant development of breast cancer, molecular strategies that aim to downregulate this expression have become highly attractive approaches to treating breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.